Summary & Overview
CPT 0206U: Discern™ Skin Specimen PKCε Assay for Alzheimer Disease
CPT code 0206U is a Proprietary Laboratory Analyses (PLA) code that identifies the Discern™ test by NeuroDiagnostics, a laboratory assay that uses morphometric imaging and protein kinase C–epsilon (PKCε) biomarker measurement on cultured skin specimens to assist in identifying Alzheimer disease. As a PLA code, 0206U is tied to a single manufacturer's proprietary test, which has implications for coding specificity, payer coverage determinations, and lab billing workflows nationally. Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn what CPT code 0206U represents clinically and operationally, how it typically fits into diagnostic pathways for suspected Alzheimer disease, and which major payers are relevant for coverage considerations. The publication outlines common payer interactions, typical site-of-service patterns for specimen collection and laboratory testing, and the policy and billing context that affects adoption of PLA-coded assays. It also summarizes available benchmarks and areas where policy updates or payer guidance may affect claims processing and lab reimbursement. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0206U is a Proprietary Laboratory Analyses (PLA) code that describes the Discern™ test by NeuroDiagnostics. The test analyzes a cultured skin specimen using morphometric imaging and measurement of the protein kinase C–epsilon (PKCε) biomarker to aid in identification of Alzheimer disease. This code represents a single, manufacturer-specific laboratory assay provided by NeuroDiagnostics.
-
Service type: Laboratory diagnostic assay involving cultured skin specimen analysis
-
Typical site of service: Clinical laboratory or specialized diagnostic laboratory (specimen collection may occur in outpatient clinic or ambulatory setting)
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult with progressive cognitive decline, memory loss, or clinical features concerning for early Alzheimer disease evaluated in a neurology or memory clinic. The patient undergoes a skin punch biopsy to obtain a small cultured skin specimen. The specimen is sent to NeuroDiagnostics for the proprietary Discern™ assay (0206U), which includes morphometric imaging and protein kinase C–epsilon (PKCε) biomarker measurements to aid in identifying Alzheimer disease pathology. The clinical workflow: the neurologist or geriatrician documents cognitive exam findings and orders the test; a dermatology or neurology clinician performs the skin punch biopsy during an outpatient visit (typical site of service: outpatient physician office or ambulatory surgical center; laboratory processing occurs at the proprietary testing laboratory); the specimen is shipped under chain-of-custody to the vendor laboratory; the laboratory performs culture, morphometric imaging, and PKCε assays and reports a result that is incorporated into the patient’s diagnostic evaluation and care plan. Indications include diagnostic clarification in patients with suspected Alzheimer disease, particularly when noninvasive blood or cerebrospinal fluid biomarkers are inconclusive or unavailable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no modifier applies |
26 | Professional component | Use when billing only the professional interpretation component of a test report if separated |
TC | Technical component | Use when billing only the technical component (laboratory processing) of the test |
QK | CLIA waived test performed by subcontractor | Use when a subcontractor performed the waived portion under CLIA arrangements (if applicable) |
QX | Modifier indicating services by a certified nurse-midwife, physician assistant, etc. | Use when an auxiliary clinician performs the biopsy under appropriate supervision rules |
QY | Services furnished under a physician's supervision by auxiliary personnel | Use when specimen collection is performed by auxiliary staff under physician supervision |
52 | Reduced services | Use when a portion of the test or specimen processing was not completed as documented |
53 | Discontinued procedure | Use when specimen collection was begun but terminated due to patient instability or other documented reason |
76* | Repeat procedure by same physician | Data not provided in raw list; not included per instructions |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RH0000X | Neurology | Neurologists order and interpret dementia diagnostic testing |
| 207P00000X | Psychiatry | Geriatric psychiatrists involved in cognitive disorder evaluation |
| 207N00000X | Geriatric Medicine | Geriatricians managing dementia evaluation and ordering tests |
| 207L00000X | Dermatology | Dermatologists frequently perform skin punch biopsies for specimen collection |
| 2084P0800X | Clinical Laboratory | Laboratory directors and specialized testing labs performing the assay |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
G30.0 | Alzheimer disease with early onset | Indicative of Alzheimer pathology in younger patients where confirmatory biomarker testing may be sought |
G30.1 | Alzheimer disease with late onset | Common diagnostic indication for biomarker testing to support clinical diagnosis in older adults |
G30.9 | Alzheimer disease, unspecified | Used when Alzheimer disease is suspected but not otherwise specified; test may support diagnosis |
F02.80 | Dementia in other diseases classified elsewhere without behavioral disturbance | Dementia phenotype requiring further evaluation including biomarker testing |
F03.90 | Unspecified dementia without behavioral disturbance | Symptom-based diagnosis where ancillary testing can aid in etiologic clarification |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0212U | Proprietary laboratory analysis; amyloid beta oligomer assay (example PLA code) | Other proprietary biomarker assays may be ordered in parallel or as alternative molecular diagnostics in dementia evaluation |
11102 | Tangential biopsy of skin, single lesion; excision less than 1.1 cm | Procedure code for skin biopsy techniques that may be used to obtain the specimen prior to laboratory testing |
87070 | Culture, bacterial; any source, aerobic, with isolation and presumptive identification of colonies | General microbiology culture code; included here as an example of laboratory processing codes that might accompany specimen handling (not specific to proprietary assay) |
88342 | Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain | Ancillary tissue-based testing that may be performed on skin specimens in other diagnostic workflows |